PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tamsulosin with solifenacin - Benign prostatic hyperplasia

PAD Profile : Tamsulosin with solifenacin - Benign prostatic hyperplasia

Keywords :
BPH, LUTS, urinary retention
Brand Names Include :
Vesomni

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
03 June 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

18 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN does not recommend the use of the combination product VesomniĀ® (tamsulosin & solifenacin) as a treatment option for lower urinary tract symptoms in men and has assigned a BLACK traffic light status to this treatment. Patients whose treatment was initiated by the NHS before this recommendation was made, must be reviewed by their NHS consultant but should be able to continue treatment until, the patient and their NHS consultant consider it appropriate to stop.

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.01. Drugs for urinary retention
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More